Aldeyra Therapeutics (ALDX) said Thursday it has resubmitted a new drug application to the US Food and Drug Administration for topical ocular reproxalap, which is being developed as a treatment for signs and symptoms of dry eye disease.
Included in the resubmission were previously disclosed results from a completed trial requested by the FDA following a review of the prior NDA, the company said.
Price: 5.28, Change: -0.02, Percent Change: -0.38
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments